Management of metastatic castration-resistant prostate cancer following docetaxel

被引：1
作者：
Beuzeboc, Philippe [1 ]
Ropert, Stanislas [2 ]
Goldwasser, Francois [2 ]
Zerbib, Marc [3 ]
机构：
[1] Inst Curie, Dept Med Oncol, F-75005 Paris, France
[2] Hop Cochin, Med Oncol Serv, F-75014 Paris, France
[3] Hop Cochin, Serv Urol, F-75014 Paris, France
来源：
BULLETIN DU CANCER | 2012年 / 99卷
关键词：
metastatic castration-resistant prostate cancer; following docetaxel; abiraterone acetate; cabazitaxel; alpharadin; MDV3100; TAK700; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; PLUS PREDNISONE; PHASE-II; MITOXANTRONE; MULTICENTER;
D O I：
10.1684/bdc.2012.1560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Abiraterone acetate and cabazitaxel have shown an overall survival benefit in patients with metastatic castration-resistant prostate cancer following docetaxel failure. Both have been approved in this indication. The search, follow-up and characterisation of circulating tumor cells should help for the response evaluation and the choice between the two treatments. Recently, alpharadin (radium-223 chloride) has demonstrated also an overall survival advantage in a large phase III trial. Other hormone therapies as MDV3100 or TAK700 are very promising. In undifferentiated cancers with neuroendocrine features, etoposide and platinum salts combinations have shown low efficiency
引用
收藏
页码：S66 / S72
页数：7
相关论文
共 20 条
  • [1] Circulating Tumor Cells as Biomarkers in Prostate Cancer
    Danila, Daniel C.
    Fleisher, Martin
    Scher, Howard I.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (12) : 3903 - 3912
  • [2] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
    Danila, Daniel C.
    Morris, Michael J.
    de Bono, Johann S.
    Ryan, Charles J.
    Denmeade, Samuel R.
    Smith, Matthew R.
    Taplin, Mary-Ellen
    Bubley, Glenn J.
    Kheoh, Thian
    Haqq, Christopher
    Molina, Arturo
    Anand, Aseem
    Koscuiszka, Michael
    Larson, Steve M.
    Schwartz, Lawrence H.
    Fleisher, Martin
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1496 - 1501
  • [3] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) : 1995 - 2005
  • [4] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    [J]. LANCET, 2010, 376 (9747) : 1147 - 1154
  • [5] Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
    Eymard, Jean-Christophe
    Oudard, Stephane
    Gravis, Gwenaelle
    Ferrero, Jean-Marc
    Theodore, Christine
    Joly, Florence
    Priou, Frank
    Krakowski, Ivan
    Zannetti, Alain
    Thill, Laurence
    Beuzeboc, Philippe
    [J]. BJU INTERNATIONAL, 2010, 106 (07) : 974 - 978
  • [6] Flechon A, 2011, ANN ONCOL
  • [7] Hussain M, 2011, P ASCO
  • [8] Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
    Loriot, Y.
    Massard, C.
    Gross-Goupil, M.
    Di Palma, M.
    Escudier, B.
    Bossi, A.
    Fizazi, K.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (04) : 703 - 708
  • [9] The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
    Loriot, Yohann
    Massard, Christophe
    Gross-Goupil, Marine
    Di Palma, Mario
    Escudier, Bernard
    Bossi, Alberto
    Chauchereau, Anne
    Fizazi, Karim
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1770 - 1772
  • [10] Michaelson MD, 2011, P ASCO
12